Hexagon Bio-Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.20 Cr
as on 24-10-2024
- Paid Up Capital ₹ 2.18 Cr
as on 24-10-2024
- Company Age 18 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.53 Cr
as on 24-10-2024
- Satisfied Charges ₹ 4.79 Cr
as on 24-10-2024
- Revenue 2.22%
(FY 2023)
- Profit 125.15%
(FY 2023)
- Ebitda 1744.69%
(FY 2023)
- Net Worth 68.11%
(FY 2023)
- Total Assets -6.84%
(FY 2023)
About Hexagon Bio-Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.20 Cr and a paid-up capital of Rs 2.18 Cr.
The company currently has active open charges totaling ₹3.53 Cr. The company has closed loans amounting to ₹4.79 Cr, as per Ministry of Corporate Affairs (MCA) records.
Shridhar Kolya and Shashirekha Kolya serve as directors at the Company.
- CIN/LLPIN
U24232KA2006PTC040046
- Company No.
040046
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Jul 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Hexagon Bio-Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shridhar Kolya  | Whole-Time Director | 26-Jul-2006 | Current |
| Shashirekha Kolya | Additional Director | Current |
Financial Performance of Hexagon Bio-Pharma.
Hexagon Bio-Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.22% increase. The company also saw a substantial improvement in profitability, with a 125.15% increase in profit. The company's net worth Soared by an impressive increase of 68.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hexagon Bio-Pharma?
In 2023, Hexagon Bio-Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Tata Capital Housing Finance Limited Creation Date: 24 Jan 2024 | ₹3.46 Cr | Open |
Vijaya Bank Creation Date: 29 Aug 2008 | ₹0.68 M | Open |
Others Creation Date: 19 Jan 2021 | ₹3.00 Cr | Satisfied |
How Many Employees Work at Hexagon Bio-Pharma?
Hexagon Bio-Pharma has a workforce of 27 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hexagon Bio-Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hexagon Bio-Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
